Predict the risk of a future symptomatic kidney stone after the last symptomatic stone.
The Recurrence Of Kidney Stone (2018) prediction tool was developed using a historical cohort study of all 3364 first-time confirmed symptomatic kidney stone formers in Olmsted County, Minnesota, USA between 1984 and 2012 with follow-up through 2017. This tool is intended for predicting the risk of a subsequent symptomatic kidney stone episode resulting in clinical care that takes into account the number of past confirmed symptomatic stone episodes, years since the last episode, and multiple risk factors at the time of the last episode. The risk of symptomatic recurrence in 5 years can range from 0.9% to 94%. A strength of the study used to develop this tool was the manual validation and comprehensive medical record review of each participant through the resources of the Rochester Epidemiology Project. Limitations were lack of external validation and the tool only predicts the risk of confirmed symptomatic recurrence episodes that result in clinical care. The tool is unlikely to be valid in patients with rare kidney stone compositions or rare genetic disorders that lead to kidney stones.
Vaughan LE, Enders FT, Lieske JC, Pais VM, Rivera ME, Mehta RA, Vrtiska TJ, Rule AD.
The Recurrence Of Kidney Stone (2018) prediction tool was developed using a historical cohort study of all 3364 first-time confirmed symptomatic kidney stone formers in Olmsted County, Minnesota, USA between 1984 and 2012 with follow-up through 2017. This tool is intended for predicting the risk of a subsequent symptomatic kidney stone episode resulting in clinical care that takes into account the number of past confirmed symptomatic stone episodes, years since the last episode, and multiple risk factors at the time of the last episode. The risk of symptomatic recurrence in 5 years can range from 0.9% to 94%. A strength of the study used to develop this tool was the manual validation and comprehensive medical record review of each participant through the resources of the Rochester Epidemiology Project. Limitations were lack of external validation and the tool only predicts the risk of confirmed symptomatic recurrence episodes that result in clinical care. The tool is unlikely to be valid in patients with rare kidney stone compositions or rare genetic disorders that lead to kidney stones.
Vaughan LE, Enders FT, Lieske JC, Pais VM, Rivera ME, Mehta RA, Vrtiska TJ, Rule AD.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
